EMCC European Monitoring Centre on Change

Laboratoire français du fractionnement et des biotechnologies

Company/Organisation:
Laboratoire français du fractionnement et des biotechnologies

Geographic Location

Country: France

Company

Sector: Professional services
Scientific research and development
72.11 - Research and experimental development on biotechnology
Number Employed: 1800
Group: Etat Français

Employment Effects

Announcement Date: 06-02-2019
Planned Job Reductions min: 120
Planned Job Reductions max: 120
Type of Restructuring: Internal restructuring
Employment Effect Start: 01-04-2019

Additional Information

The Laboratoire français du fractionnement et des biotechnologies (LFB) has announced 120 job cuts as part of a reorganisation aimed at refocusing its activities. The pharmaceutical group, 100% state-owned, employs currently more than 2,300 people, including 1,800 in France. It is specialised in drugs derived from plasma or recombinant proteins, used in immunology, hematology and emergency medicine.

The reorganisation responds to criticism from the Court of Auditors (responsible for ensuring the proper use of public money) which, in its annual report, pointed to an 'over-ambitious' strategy of diversification in biotechnology. Decrease in production, failures at key points in drug manufacturing, governance problems, investment in biotechnology R&D that has yet to yield results are amog the issues listed in the Court of Auditors' report. The report says these issues caused a loss of €152 million representing more than 30% of LFB's turnover in 2017.

Sources: